Interventions for age-related diseases: Shifting the paradigm

Figueira, Inês; Fernandes, Adelaide; Djordjevic, Aleksandra Mladenovic; López-Contreras, Andrés J.; Henriques, Catarina M.; Selman, Colin; Ferreiro, Elisabete; Gonos, Efstathios S.; Trejo, José Luís; Misra, Juhi; Rasmussen, Lene Juel; Xapelli, Sara; Ellam, Timothy; Bellantuono, Ilaria

doi:10.1016/j.mad.2016.09.009

Cited by 68 publications

(49 citation statements)

References 441 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experimental evidence is accumulating that inhibition of PAPP‐A has the potential to promote healthy longevity. It is clearly advantageous that targeting of PAPP‐A has the benefit of a single intervention that affects multiple adverse changes with age, not just a single condition (Figueira et al ., ). PAPP‐A is present in the extracellular environment, and its activity is therefore amenable to pharmacologic intervention.…”

Section: Resultsmentioning

confidence: 97%

PAPP-A: a promising therapeutic target for healthy longevity

Conover

Oxvig

2016

Aging Cell

View full text Add to dashboard Cite

SummaryPregnancy‐associated plasma protein‐A (PAPP‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP‐A represents a novel approach to indirectly decrease the availability of bioactive IGF. Here, we will review data in support of PAPP‐A as a therapeutic target to promote healthy longevity.

show abstract

Section: Resultsmentioning

confidence: 97%

PAPP-A: a promising therapeutic target for healthy longevity

Conover

Oxvig

2016

Aging Cell

View full text Add to dashboard Cite

show abstract

Section: Maturing Fieldmentioning

confidence: 99%

“…A review of more than 400 studies of people and animal models indicates that similar mechanisms underlie six conditions 2 . These can involve DNA damage, such as that caused by free radicals; cellular senescence (in which cells stop dividing and start secreting inflammatory factors); or inflammation and autophagy (the degradation of organelles, misfolded proteins and so on) 2 .This may explain why people over 65 are at a higher risk than younger people of developing more than one disease at the same time. In the United States, 7 out of 10 people over 65 with diabetes will die of heart disease, for instance.…”

mentioning

confidence: 99%

Find drugs that delay many diseases of old age

Bellantuono

2018

Nature

Self Cite

View full text Add to dashboard Cite

COMMENT Studies of ageing have tended to focus on lifespan rather than on years of good health.© 2 0 1 8 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d . a network of academic and industry scientists, clinicians and regulators called COST Action BM1402: MouseAGE. The network, which is funded by the European Union, has worked with other experts in these domains worldwide. MATURING FIELDOver the past decade, understanding of the physiological changes that occur as people age has improved a great deal.Common mechanisms seem to underpin several age-related diseases, including diabetes, Parkinson's disease and Alzheimer's. A review of more than 400 studies of people and animal models indicates that similar mechanisms underlie six conditions 2 . These can involve DNA damage, such as that caused by free radicals; cellular senescence (in which cells stop dividing and start secreting inflammatory factors); or inflammation and autophagy (the degradation of organelles, misfolded proteins and so on) 2 .This may explain why people over 65 are at a higher risk than younger people of developing more than one disease at the same time. In the United States, 7 out of 10 people over 65 with diabetes will die of heart disease, for instance.It is also becoming clear that one agerelated disease can accelerate the onset of others. A 2014 study 3 showed that people older than 75 who already had diabetes, say, were more than twice as likely to develop another disease over the next three years than those who were healthy at the beginning of the study.Also, between one-quarter and half of people over the age of 80 become frail. The accumulation of deficits makes it harder for them to recover from an infection, fall or other minor stressor 4 . It is unclear whether multimorbidity leads to frailty or vice versa, or whether they are independent.Until now, ageing research has focused mainly on single diseases, or on delaying death. This means that the fundamental mechanisms of ageing as targets for the treatment or prevention of several age-related conditions are being missed. What's more, patients with multimorbidity are being exposed to many drugs at once, often with adverse effects 5 . THREE STEPS TO TRANSLATIONResearch in mice over the past few years suggests that it might be possible to delay the decline of many tissues and the onset of disease. Drugs such as rapamycin, metformin or senolytics (which remove senescent cells), can slow the development of cataracts, osteoarthritis, osteoporosis, the loss of muscle mass and can improve cardiac function 2,6-8 .If these are to become useful in people, three advances must be made. There is no standardized definition of multimorbidity. Some researchers use the term to describe the co-occurrence of 2 diseases, some 5, others 13 and so on. This makes it hard to compare studies and to establish which diseases have a higher chance of occurring together.Agreeing to a definition will require:working out which of the 5 o...

show abstract

“…In view of the aging of the global population, the number of patients with central nervous system (CNS) diseases is gradually increasing, posing great challenges to human survival . Therefore, this review mainly focuses on the diagnosis and treatment of various CNS diseases.…”

Section: Introductionmentioning

confidence: 99%

Recent Progress of Nanomedicine in the Treatment of Central Nervous System Diseases

Feng

Wang

Xue

2020

Advanced Therapeutics

View full text Add to dashboard Cite

Central nervous system (CNS) diseases, mainly including neurodegenerative diseases and psychiatric diseases, have become the leading cause of death and disability in the world today, which bring huge suffering to both patients and their families. Nanomedicine is an emerging and rapidly evolving discipline that mainly involves the application of nanoparticles in the diagnosis and treatment of various diseases. Although many challenges in the clinical application of nanomedicine still exist, the prospects for development cannot be ignored. Furthermore, better outcomes for patients with CNS diseases can be expected with the rapid development of nanotechnology in diagnosis and treatment. In the present review, an overview is given of the outstanding recent progress of nanomedicine from three aspects: drug delivery, imaging, and therapy in CNS diseases.

show abstract

Interventions for age-related diseases: Shifting the paradigm

Cited by 68 publications

References 441 publications

PAPP-A: a promising therapeutic target for healthy longevity

PAPP-A: a promising therapeutic target for healthy longevity

Find drugs that delay many diseases of old age

Recent Progress of Nanomedicine in the Treatment of Central Nervous System Diseases

Contact Info

Product

Resources

About